Patient-Focussed Drug Development | Leadership of Diverse High-Performance Teams | Climbing enthusiast
Tomorrow at 9AM EST (15.00 CET) I will be talking about Multidimensional Thresholding (MDT) at the IAHPR seminar. This will include results from a study where we compared preference information from a discrete choice experiment (DCE) to preference information from MDT. Reed Johnson will be the discussant. Please join via this link: https://lnkd.in/ev-mM2ti. Why attend? There is an increasing push to widen the preference toolbox beyond DCEs, both from the scientific community as well as decision makers. This push is largely grounded in sample size requirements of DCEs that would potentially prevent preference research in rare or ultra rare diseases as well as small minorities. This is concerning if we think that all patient voices matter. For instance, "patient values related to rare diseases" is listed as a broadly applicable preference sensitive area by the FDA: https://lnkd.in/ef3jRdTH Advancing a novel preference instrument is exciting and lots remains to be done! Let's work on this together as one scientific community. One main motivation for me to give this seminar is to encourage you all to chip in with valuable methods work, inspiring ideas, and/or applications. Thank you IAHPR Office for the invitation!
Patient preference and benefit-risk leader, chief scientist at Kielo Research, co-founder at Valorem Health
9moTommo approves